



NEWS



December 18, 2009

>> Tibotec-Virco Virology BVBA acquires Lab Tracker

Tibotec-Virco Virology BVBA acquires Lab Tracker, an HIV specific electronic medical record software system

Lab Tracker™ HIV, a customized electronic medical record (EMR) system was acquired from Ground Zero Software in the United States, and is a full-service, scalable software platform designed to meet the complex disease-management needs of people with HIV and the practitioners who treat them. Virco has full global rights to the product.

The acquisition of Lab Tracker™ HIV is a major step forward in expanding our company's health information technology offering, and a logical move following our long-standing credentials in HIV bioinformatics and drug resistance interpretation including our lead product, virco@TYPE HIV-1, said Werner Verbiest, General Manager Worldwide, Virco. We will continue to explore new technology opportunities that are consistent with our commitment to enhancing the care of people living with HIV and other infectious diseases by enhancing clinical decision-making.


 [read more in the press release](#)

>> EACS 2009

From November 11th to 14th 2009, Virco attended the [European AIDS Conference \(EACS\)](#) in Cologne Germany, a regular biannual meeting on the HIV conference calendar.

Virco presented three posters, as well as interacting with attendees:

- "A Potency Weighted Sensitivity Score Enables a Transparent and Accurate Prediction of the Activity of a Combination Therapy" by [Bart Winters et al.](#)
- "Rare HIV-1 drug resistance mutations exert subtle synergistic and antagonistic effects in the context of the genetic background" by [Margriet Van Houtte et al.](#)
- "Validation of V3-loop based genotyping by direct comparison with 454 pyrosequencing in patients eligible for Maraviroc initiation" by Ina Vandenbroucke et al.

 [read more](#)

>> AASLD

The 60th [American Association for the Study of Liver Diseases \(AASLD\)](#) annual Liver Meeting was held in Boston, Massachusetts from 30th October to 3rd November, and some 7,000 specialists and allied professionals attended a diverse meeting on viral hepatitis and other liver diseases. Some key highlights for chronic hepatitis C follow:

- This year saw continuing presented data on the Specifically Targeted Antiviral Therapy for Hepatitis C (STAT-C) agents in development, and in particular lead NS3 protease and NS5B polymerase agents in phase III and II respectively from many leading pharmaceutical and biotech companies.
- Studies into interferon and ribavirin-sparing combinations of Specifically Targeted Antiviral Therapy for Hepatitis C (STAT-C) antivirals have now been initiated, and the first, INFORM-1, reported initial 14 day findings. The potential for replacing current standard of care with oral antiviral combinations is very keenly anticipated.
- From a diagnostic perspective, there was considerable interest in potential host genetic biomarkers for predicting response to current standard of care (pegylated interferon and ribavirin). Whereas no single biomarker is likely to dominate as the ultimate predictive test according to the investigators, they will potentially allow clinicians to consider which approach to take in tailoring treatment for chronic hepatitis C.


 [read more](#)

>> CROI 2010

The International [Conference on Retroviruses and Opportunistic Infections \(CROI 2010\)](#) will take place in San Francisco California from February 16-19, 2010.

Virco is proud to announce the acceptance of three scientific posters with our external collaborators:

- "Resistance Associated Mutations to Etravirine (TMC-125) in Antiretroviral Naïve Patients infected with non-B HIV-1 subtypes"; Maïga AI, et al.
- "Primary Mutations Associated with Resistance to Raltegravir are not Detectable by Pyrosequencing in Integrase-Inhibitors Naïve Patients"; Ceccherini-Silberstein F, et al.
- "Estimation of Virological Residual Activity on a Regimen of Abacavir/Zidovudine/Lamivudine (ABC/3TC/ZDV)"; Dunn D, et al.

 [read more](#)

>> HIV Clinical Update - December 2009

New on the Vircolab.com web site is the December Clinical Update, "An analysis of the relative contributions of specific drugs to virological response" by Winters B, et al.

This exploratory analysis demonstrated the potential for increased predictive accuracy for sensitivity scores incorporating both accurate assessments of resistance, such as those provided by virco@TYPE HIV-1, and weighting based on data driven analyses of intrinsic drug potency. Additional studies will no doubt be needed to assess the potential to incorporate weighted scores into future clinical use.

 [Please click here for the full article](#)

VIRCO BVBA
Gen. De Wittelaan L11B3
B-2800 Mechelen
Belgium
Tel: + 32 15 46 1000
Fax: + 32 15 46 1955

Virco Lab Inc.
430 Route 22 East
Bridgewater, NJ 08807
Tel: (908) 541-4499
Fax: (908) 725-6073